Melanocortin System and Skin Color: Alpha-MSH Explained

Melanocortin Peptides and Tanning

13 amino acids

Alpha-MSH, a 13-amino-acid peptide fragment of POMC, binds MC1R on melanocytes and switches pigment production from red/yellow pheomelanin to brown/black eumelanin.

Bohm et al., J Eur Acad Dermatol Venereol, 2025

Bohm et al., J Eur Acad Dermatol Venereol, 2025

View as image

Every time you tan in the sun, you are watching the melanocortin system at work. Ultraviolet radiation hits your skin, keratinocytes release alpha-MSH, that 13-amino-acid peptide binds to MC1R receptors on melanocytes, and those cells shift from producing yellow-red pheomelanin to brown-black eumelanin. This is the same molecular pathway that determines baseline skin color across human populations, that drives the action of Melanotan I and Melanotan II, and that connects pigmentation to sexual arousal through shared receptor biology.

The melanocortin system is one of the most pharmacologically active peptide signaling networks in the body. Understanding it explains not only skin color but also why Melanotan II has serious side effects, why red-haired people have elevated melanoma risk, and why the same peptide system that controls pigmentation also regulates appetite, inflammation, and sexual function.

POMC: The Master Precursor

The melanocortin system begins with a single gene product: pro-opiomelanocortin (POMC), a 241-amino-acid precursor peptide expressed in the anterior pituitary, the hypothalamus, and the skin. POMC is cleaved by prohormone convertases into multiple bioactive peptides, each with distinct functions.

The cleavage products include ACTH (adrenocorticotropic hormone, which drives cortisol production), beta-endorphin (an endogenous opioid), and three melanocyte-stimulating hormones: alpha-MSH, beta-MSH, and gamma-MSH. Alpha-MSH consists of amino acids 1-13 of the ACTH sequence, meaning ACTH itself can activate melanocortin receptors, which explains why people with Addison's disease (who overproduce ACTH) develop skin darkening.

Ronnekleiv and Bosch (2025) mapped the early development of hypothalamic POMC neurons in eNeuro, demonstrating that these cells establish their peptide-producing identity early in development and serve as critical nodes connecting pigmentation, metabolism, and stress response circuitry.^[4]

The connection between POMC and appetite regulation is direct: alpha-MSH released from hypothalamic POMC neurons activates MC4R in the brain to suppress feeding. Mutations in POMC, MC4R, or the processing enzymes that generate alpha-MSH cause severe early-onset obesity.

The MC1R Switch: Eumelanin vs Pheomelanin

Melanocytes, the pigment-producing cells in the basal layer of the epidermis, synthesize melanin through a process called melanogenesis. The type of melanin produced depends on whether MC1R is activated.

When alpha-MSH binds MC1R, the receptor activates adenylyl cyclase, which increases intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). CREB activates transcription of MITF (microphthalmia-associated transcription factor), which in turn upregulates the enzymes tyrosinase, TRP-1, and TRP-2. These enzymes drive the synthesis of eumelanin, the brown-black pigment that provides effective UV protection.

When MC1R is not activated, or when it is blocked by the endogenous antagonist agouti signaling protein (ASIP), cAMP levels remain low. Under these conditions, melanocytes produce pheomelanin instead: a yellow-red pigment that provides minimal UV protection and generates reactive oxygen species when exposed to UV radiation.

Bohm et al. (2025) published a comprehensive overview in the Journal of the European Academy of Dermatology and Venereology on the benefits and risks of chronic MC1R activation. They documented that MC1R signaling extends well beyond pigmentation, influencing DNA repair, anti-oxidant defense, and anti-inflammatory pathways in melanocytes and other cell types.^[1]

MC1R Variants and Human Skin Color Diversity

MC1R is one of the most polymorphic genes in the human genome. Over 80 coding variants have been identified. The distribution of these variants across human populations directly tracks with latitude and UV exposure intensity, providing one of the clearest examples of natural selection acting on a peptide receptor gene.

Loss-of-function MC1R variants (often called "R" alleles) reduce the receptor's ability to respond to alpha-MSH. Carriers produce more pheomelanin relative to eumelanin. Individuals homozygous for strong R alleles typically have red hair, fair skin, freckling, and poor tanning response. They also have elevated risk of melanoma and other skin cancers, because pheomelanin is not only less photoprotective than eumelanin but actively generates DNA-damaging free radicals under UV exposure.

The MC1R variants most strongly associated with red hair phenotype include R151C, R160W, and D294H. These variants reduce cAMP signaling by 50 to 90% compared to wild-type MC1R. Partial loss-of-function variants (sometimes called "r" alleles) produce intermediate effects: lighter skin, tendency toward freckling, but not necessarily red hair.

Habbema et al. (2017) reviewed the risks of unregulated use of alpha-MSH analogues in the International Journal of Dermatology, noting that individuals with MC1R variants may respond differently to synthetic melanocortin agonists, with potentially unpredictable effects on melanocyte proliferation and melanoma risk.^[5]

Beyond Pigmentation: Alpha-MSH as Anti-Inflammatory Peptide

The melanocortin system does far more than control skin color. Alpha-MSH and its C-terminal tripeptide fragment KPV (Lys-Pro-Val) have potent anti-inflammatory properties.

Brzoska et al. (2010) reviewed the anti-inflammatory effects of alpha-MSH-related peptides in Advances in Experimental Medicine and Biology. They documented that alpha-MSH suppresses production of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and upregulates anti-inflammatory mediators (IL-10) through MC1R signaling on immune cells including macrophages, neutrophils, and lymphocytes.^[2]

This anti-inflammatory activity explains why KPV targets NF-kB to reduce gut inflammation and why melanocortin peptides are being investigated for conditions ranging from inflammatory bowel disease to sepsis to neuroinflammation.

The Appetite Connection

Alpha-MSH's role in appetite regulation is mediated primarily through MC4R in the hypothalamus, not MC1R in the skin. But the connection exists because both functions originate from the same POMC precursor.

Hsieh et al. (2021) demonstrated in Biomedicines that depletion of alpha-MSH in animal models induced insatiable appetite and significant weight gain. The finding confirmed that alpha-MSH is a critical satiety signal and that disruptions in POMC processing can simultaneously affect both pigmentation and metabolic regulation.^[3]

Qamar et al. (2024) reviewed setmelanotide, a synthetic MC4R agonist approved for rare genetic obesity conditions caused by POMC, PCSK1, or LEPR deficiencies. Published in TouchREVIEWS in Endocrinology, they documented how targeted melanocortin agonism at MC4R can restore satiety signaling in patients with specific genetic defects in the POMC pathway.^[6]

Solak and Gokcen (2025) published data in BMC Psychiatry showing that POMC levels differ between patients with bipolar and unipolar depression, suggesting that melanocortin system dysregulation extends into psychiatric conditions as well.^[7]

Synthetic Alpha-MSH Analogs: From Afamelanotide to Melanotan

The pharmaceutical exploitation of the melanocortin pigmentation pathway has followed two tracks: legitimate drug development and underground self-experimentation.

Afamelanotide (Scenesse), a synthetic alpha-MSH analog, is FDA-approved for erythropoietic protoporphyria (EPP), a rare genetic condition where patients cannot tolerate sunlight. By activating MC1R, afamelanotide increases eumelanin production and extends the time patients can spend in light without triggering painful phototoxic reactions. This represents the only FDA-approved drug that directly exploits the alpha-MSH/MC1R pigmentation pathway.

Melanotan I and Melanotan II are research peptides that have been widely used without regulatory approval for tanning purposes. Melanotan I (afamelanotide) is selective for MC1R. Melanotan II is non-selective, activating MC1R (pigmentation), MC3R and MC4R (appetite, sexual function), and MC5R (sebaceous gland function). This lack of selectivity explains why Melanotan II produces both tanning and sexual arousal effects, along with nausea and other side effects.

Tomassi et al. (2022) published in the Journal of Medicinal Chemistry on using constrained peptide chemistry (CLIPS technology) to create functionally selective melanocortin receptor agonists from the Melanotan-II backbone. The goal: separate the desired MC1R pigmentation activity from the unwanted MC3R/MC4R metabolic and sexual side effects.^[8]

Yassin et al. (2025) reported a case of oral mucosal malignant melanoma potentially associated with Melanotan II nasal spray use, published in the International Journal of Oral and Maxillofacial Surgery.^[9] This case adds to the concern documented by Habbema et al. (2017) that chronic unregulated melanocortin agonism may promote melanocytic proliferation in ways that increase cancer risk.^[5]

Chawathe and Sharma (2026) investigated the stability profile of therapeutic alpha-MSH analogues in the Journal of Pharmaceutical and Biomedical Analysis, addressing a practical challenge: alpha-MSH degrades rapidly in biological fluids, and creating stable formulations is essential for clinical applications.^[10]

UV Exposure and the Tanning Response

The tanning response is a coordinated peptide signaling event. When UV radiation (particularly UVB at 280-315 nm) reaches the epidermis, it causes direct DNA damage in keratinocytes. This damage activates p53, which upregulates transcription of the POMC gene in keratinocytes. The keratinocytes then process and secrete alpha-MSH, which acts in a paracrine fashion on neighboring melanocytes.

The melanocytes respond by increasing eumelanin production through the MC1R/cAMP/MITF pathway described above. Newly synthesized melanin is packaged into melanosomes and transferred to surrounding keratinocytes through dendritic processes. The keratinocytes position melanosomes as a cap over their nuclei, physically shielding their DNA from further UV damage.

This entire process takes 48 to 72 hours, which is why tanning appears days after sun exposure rather than immediately. The delay reflects the time required for alpha-MSH signaling, enzyme upregulation, melanin synthesis, and melanosome transfer.

Individuals with loss-of-function MC1R variants cannot effectively execute this protective response. Their melanocytes receive the alpha-MSH signal but cannot transduce it into eumelanin production. Instead, they continue producing pheomelanin, which absorbs UV but generates free radicals rather than dissipating the energy safely.

Why This System Matters

The melanocortin pigmentation pathway is a case study in peptide biology's complexity. A single precursor (POMC) generates a peptide (alpha-MSH) that binds a single receptor (MC1R) to control a binary switch (eumelanin vs pheomelanin). The simplicity of the pathway is deceptive. MC1R variants explain a significant portion of human skin color variation. The same peptide that controls pigment also regulates inflammation and appetite through parallel receptor systems. And synthetic analogs of alpha-MSH have produced both an FDA-approved drug for a rare disease and a black-market tanning industry with documented cancer risks.

The Bottom Line

The melanocortin system controls human skin pigmentation through alpha-MSH, a 13-amino-acid peptide that binds MC1R on melanocytes and switches pigment production from pheomelanin (yellow-red, UV-vulnerable) to eumelanin (brown-black, UV-protective). MC1R is one of the most polymorphic genes in the human genome, with over 80 variants that directly influence skin color, tanning ability, and melanoma risk across populations. Alpha-MSH has additional functions in anti-inflammatory signaling and, through its shared POMC origin, in appetite regulation. Synthetic alpha-MSH analogs range from the FDA-approved afamelanotide for erythropoietic protoporphyria to the unregulated Melanotan peptides used for tanning, which carry documented safety risks including potential melanoma promotion.

Frequently Asked Questions

What is alpha-MSH and what does it do to skin?

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide produced when the precursor protein POMC is cleaved. It binds to MC1R receptors on melanocytes in the skin and triggers production of eumelanin, the brown-black pigment that provides UV protection. Without alpha-MSH signaling, melanocytes produce pheomelanin instead, a yellow-red pigment that offers less UV protection. UV exposure stimulates keratinocytes to release more alpha-MSH, which is why skin darkens after sun exposure.

Why do redheads burn easily and have higher melanoma risk?

Red hair and fair skin result from loss-of-function variants in the MC1R gene. These variants reduce the receptor's ability to respond to alpha-MSH, so melanocytes produce more pheomelanin (red-yellow pigment) and less eumelanin (brown-black pigment). Pheomelanin provides minimal UV protection and actively generates DNA-damaging free radicals when exposed to UV radiation. Common MC1R variants like R151C and R160W reduce cAMP signaling by 50 to 90% compared to normal MC1R.

How is the melanocortin system connected to appetite?

Alpha-MSH and appetite regulation both originate from the same precursor protein, POMC. In the hypothalamus, alpha-MSH released by POMC neurons binds MC4R to suppress appetite. In the skin, alpha-MSH binds MC1R to promote pigmentation. Mutations in POMC, MC4R, or the enzymes that process POMC into alpha-MSH can cause both pigmentation abnormalities and severe early-onset obesity. Setmelanotide, an MC4R agonist, is FDA-approved for rare genetic obesity caused by POMC pathway defects.

What is the difference between eumelanin and pheomelanin?

Eumelanin is the brown-black pigment that provides effective UV radiation protection and scavenges free radicals. Pheomelanin is the yellow-red pigment that provides minimal UV protection and generates reactive oxygen species under UV exposure, potentially damaging DNA. Which type a melanocyte produces depends on MC1R activation by alpha-MSH: high cAMP (MC1R active) favors eumelanin; low cAMP (MC1R inactive) favors pheomelanin.

Is there an FDA-approved drug that works through the melanocortin pigmentation pathway?

Yes. Afamelanotide (brand name Scenesse) is an FDA-approved synthetic analog of alpha-MSH that activates MC1R to increase eumelanin production. It is approved for erythropoietic protoporphyria (EPP), a rare genetic condition where patients experience severe pain from sunlight exposure. By increasing eumelanin, afamelanotide extends the time EPP patients can spend in light. It is the only FDA-approved drug that directly targets the MC1R pigmentation pathway.

Does alpha-MSH have anti-inflammatory effects?

Yes. Alpha-MSH and its C-terminal fragment KPV suppress production of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and increase anti-inflammatory mediators (IL-10) through melanocortin receptor signaling on immune cells. This anti-inflammatory activity is independent of the pigmentation pathway and has led to research on melanocortin peptides for conditions including inflammatory bowel disease, sepsis, and neuroinflammation.